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ABSTRACT 
Objective: Aim of the present study was the optimization of the sustained release (SR) layer of isosorbide dinitrate (ISDN) 40 mg and compressed with the 
immediate-release (IR) layer of hydralazine hydrochloride (HHC) 25 mg to decrease the dosing frequency and development of a novel b. i. d dosage form. 
Methods: Drug excipients compatibility study was carried out by FT-IR and a preliminary study was conducted for screening of polymer. The 
amount of HPMC K100M (X1) and the amount of Polyoxtm WSR303 (X2) were chosen as independent variables in 32full factorial designs. While % 
cumulative drug releases at 1 h (Q1) (Y1), % cumulative drug release at 2 h (Q2) (Y2), % cumulative drug release at 4 h (Q4) (Y3) and % cumulative 
drug release at 6 h (Q6) (Y4), were taken as dependent variables and statistically evaluation by using sigma plot 13.0. In the present study, according 
to the U. S. P. 2007 the following constraints were used for the selection of an optimized batch: Q1=15% to 30%, Q2=50% to 70%, Q4=65% to 85% 
and Q6>75%. To validate the evolved mathematical models, a checkpoint batch was selected from its desirability value. 
Results: FT-IR spectra show that the drug and excipients were compatible with each other. The calculated F values found for Q1, Q2, Q4, and Q6 were 
084.583, 038.188, 057.719, and 118.396, respectively. All Calculated F values are greater than the tabulated value for all dependent variables. 
Prepared checkpoint batch selected from its desirability value 1 and it gives a 93.40±1.29 % drug release within 6 h.  
Conclusion: This bilayer formulation of anti-hypertensive drugs decreases the dosing frequency of HHC and ISDN. 
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INTRODUCTION 
Hypertension affects around half of the adult population worldwide, 
being one of the most common cardiovascular disorders (CVD). It 
occurs when the high cardiac output exerts pressure on the arterial 
wall as the blood flow increases. The conventional dosage form used 
in the treatment of hypertension cannot produce the desired 
therapeutic effect for a prolonged period and thus dose fluctuation 
and missing dose chances are more. The rationale for using fixed-
dose combination therapy is to obtain increased blood pressure 
control by employing two antihypertensive drugs with different 
modes of action and enhance compliance by using a single tablet. 
Bilayer tablet is suitable for the sequential release of two drugs in 
combination, separate, and for sustained release [1, 2].  
HHC, directly acting as potent peripheral vasodilator, is widely 
prescribed in the treatment of hypertension and congestive heart 
failure by direct relaxation of arteriolar smooth muscle. ISDN is 
relaxation of vascular smooth muscle and consequent dilatation of 
peripheral arteries and veins, especially the latter. Dilatation of the 
veins promotes peripheral pooling of blood and decreases venous 
return to the heart, thereby reducing left ventricular end-diastolic 
pressure and pulmonary capillary wedge pressure. The combination 
consists of an immediate-release layer of hydralazine hydrochloride 
25 mg and SR layer of ISDN 40 mg fixed-dose that functions as a 
nitric oxide enhancer and an antioxidant that helps to prevent 
tolerance to the prolonged use of nitrate. This combination also 
balanced after-load and pre-load reduction with a lowering of 
ventricular filling pressure and systemic and pulmonic vascular 
resistance. The hemodynamic effects of the combination drug in 
heart failure include increased cardiac output [3, 4]. In the present 
study, according to the U. S. P. 2007 the following constraints were 
used for the selection of an optimized batch: Q1=15% to 30%, Q2= 
50% to 70%, Q4= 65% to 85% and Q6>75%. 
Aim of the present study was the optimization of the SR layer of ISDN 
40 mg and compressed with a pre-optimized IR layer of HHC 25 mg to 
decrease the dosing frequency and develops twice a day formulation.  
MATERIALS AND METHODS 
Materials 
HHC was kindly supplied as gift samples by Torrent 
Pharmaceuticals, Ahmedabad, Gujarat India. ISDN was supplied as 
gift samples from Cadila Pharmaceuticals Ltd, Ahmadabad, India. 
Microcrystalline cellulose (MCC), Polyoxtm WSR 303, Ethylcellulose 
(EC) were procured from Colorcon Asia Pvt. Ltd., Ahmedabad, 
Gujarat, India. Magnesium stearates, talc, sodium starch glycolate 
(SSG), croscarmellose sodium (CCS) were purchased from SD Fine 
Chemicals, Mumbai, India. All other materials and chemicals used 
were of either pharmaceutical or analytical grade.  
Drug-excipients compatibility study 
Drug excipient interaction plays a vital role in achieving the 
stability of the drug in the dosage form. Fourier transform 
infrared spectroscopy (FT-IR) was used to study the physical 
and chemical interactions between drugs and excipients. FT-IR 
spectra of ISDN and mixtures of drugs with other excipients 
were obtained by using the FT-IR instrument. (FT-IR-1700, 
Shimadzu, Kyoto, Japan) [5]. 
Preliminary screening of polymer for SR layer 
The development of a SR layer containing ISDN 40 mg by selecting 
ingredients in the appropriate amount and polymer was optimized 
thereafter. The SR layer of ISDN was prepared by the direct 
compression method. HPMC K4M, HPMC K100M, polyoxtmWSR 301 
and Polyoxtm WSR 303 were used in various amounts as shown in 
table 1. Batch T1 was prepared with HPMC K4M and polyoxtmWSR 
301. Batch T2 prepared to check the effect of HPMC K4M with 
polyoxtmWSR 301. Batch T3 and T4 were prepared with HPMC K15M 
with different grades of polyoxtmWSR. Batch T5 and T6 were 
developed to check the effect of HPMC K100M on different grades of 
polyoxtmWSR. Prepared layer was evaluated for weight variation, 
thickness, hardness, friability, disintegration time, drug content, and 
% cumulative drug release [6, 7]. 
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Table 1: Preliminary screening of polymer for SR layer 
Ingredients (mg) T1 T2 T3 T4 T5 T6 
ISDN 40 40 40 40 40 40 
MCCPH102 88.8 88.8 88.8 88.8 88.8 88.8 
HPMC K4M 60 60 - - - - 
HPMC K15M - - 60 60 - - 
HPMC K100M - - - - 60 60 
PolyoxtmWSR301 60 - 60 - 60 - 
PolyoxtmWSR303 - 60 - 60 - 60 
Quinoline yellow 0.2 0.2 0.2 0.2 0.2 0.2 
Magnesium stearate 1 1 1 1 1 1 
Total (mg/tablet) 250 
 
Optimization of polymer by using 32full factorial designs 
A 32full factorial design was used for the optimization of the SR layer. 
The formulation of factorial batches was shown in table 2. Based on 
preliminary results, the amount of HPMC K100M (X1) and the amount 
of polyoxtmWSR 303 (X2) were chosen as independent variables in 32 
full factorial designs. In this study, Q1 (Y1), Q2 (Y2), Q4 (Y3) and Q6 (Y4) 
were taken as dependent variables. Multiple linear regression analysis, 
ANOVA and graphical representation of the influence of factor by 
contour plots were performed using sigma plot 13.0 [8, 9]. The 
experimental runs and measured responses of 32 full factorial design 
batches of SR layer of ISDN 40 mg were depleted in table 4. 
 
Table 2: Formulation of factorial design batches for the immediate release layer 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
ISDN 40 40 40 40 40 40 40 40 40 
MCCPH102 88.8 78.8 68.8 78.8 68.8 58.8 68.8 58.8 48.8 
HPMC K100M 60 70 80 60 70 80 60 70 80 
polyoxtm wsr303 60 60 60 70 70 70 80 80 80 
Quinoline yellow 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
Magnesium stearate 1 1 1 1 1 1 1 1 1 
Total 250 250 250 250 250 250 250 250 250 
 
Development of bilayer tablet 
The bilayer tablet was prepared using by direct compression 
method. In this method IR layer HHN 25 mg and SR layer ISDN 40 
mg was were prepared separately and the two layers were 
compressed together. IR layer of HHN was prepared using a direct 
compression method. IR layer prepared by using a rotary tablet 
punching machine by using 8 mm flat punch on a 12-station rotary 
tablet machine [10, 11]. SR layer of ISDN was optimized by using 
32full factorial designs and it was prepared using a direct 
compression method. In this method ISDN, HPMC K100M and polyox 
WSR 303 were passed through 40# mesh and mixed well. Other 
excipients like MCC PH102 and quinoline yellow were added to the 
above mixture. Finally magnesium stearate was added to the above 
blend and mixed homogenously. The whole powder blend was 
collected for compression and 250 mg tablets were compressed 
using a rotary tablet punching machine by using 8 mm flat punch on 
a 12-station rotary tablet machine [12, 13]. 
Evaluation of bilayer tablet 
The prepared tablets were evaluated for thickness, hardness, 
friability, and disintegration time of the SR layer were measured as 
described by Nivedithaa VR et al. and Fridrun P et al. [14, 15]. 
HPLC was used for estimation of HHN and ISDN: The drug 
concentration was measured according to the reverse-phase high-
performance liquid chromatography. Analysis of sample was 
performed using a cyber lab HPLC system equipped with an LCP-100 
pump, cyber lab LC-UV100 UV detector, and RP C18 column (250 × 
4.6 mm ID, particle size 5µ) at ambient temperature. The mobile 
phase used was a mixture of methanol and distilled water 1000 ml 
containing 0.1 ml TEA each (60: 40). The pH was adjusted to 6.5. The 
flow rate was 1.0 ml per min. The detection was carried out at 215 
nm. A calibration curve was plotted for HHN and ISDN. A good linear 
relationship was observed between the concentration of the drug 
and the peak area of the drug with a correlation coefficient [16]. 
Drug content for ISDN: The drug content was carried out by 
weighing 10 tablets from each batch and calculated the average 
weight. Then the tablets were triturated and weighed accurately, 
which was equivalent to 100 mg ISDN. It was dissolved in a 100 ml 
volumetric flask containing 100 ml of 0.1N HCl and volume was 
made to 100 ml with solvent. The volumetric flask was shaken using 
a sonicator for 1 h and after suitable dilution, with 0.1N HCl the drug 
content was determined using HPLC at 215 nm.  
In vitro drug release study: In vitro release of bilayer tablets was 
determined using a USP type-II dissolution test apparatus at 100 
rpm. The dissolution was studied using 900 ml of simulated gastric 
fluid 0.1N HCl (without enzyme, pH 1.2) for the first 2 h and 
followed by a simulated intestinal fluid (without enzyme pH 6.8) for 
the remaining 10 h. The temperature was maintained at 37±0.5 °C. 5 
ml sample was taken at different time intervals up to 12 h. filter 
through Whatman filter paper and replaced by an equal volume of 
dissolution medium sample were suitably diluted and analyzed by 
HPLC at 215 nm.  
Stability study: Optimized batch was packed in aluminum foil and 
was placed for stability study at 40˚C/75% RH for 6 mo. The sample 
was evaluated after 6 mo for physical parameters and In vitro 
dissolution. The dissolution profile of the product compared using 
















Where a log is a logarithm to the base 10, n is the number of time 
points,  is the summation over all time points, Rt is the mean 
dissolution value of the reference profile at time t and Tt is the mean 
dissolution value of the test profile at the same time point. The USFDA 
draft guidance document contains more information on the similarity 
factor (f2). The value of similarity factor (f2) between 50 and 100 
suggests that the two dissolution profiles are similar [17, 18]. 
RESULTS AND DISCUSSION 
Drug-excipients compatibility study by FT-IR 
Fourier transform infrared spectroscopy (FT-IR) study was used to 
the physical and chemical interactions between drugs and 
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excipients. FT-IR spectra of ISDN with excipients were recorded 
using KBr mixing method on the FT-IR instrument. The FT-IR 
spectra of ISDN and the mixture of drugs with excipient are shown 
in fig. 1(A) and fig. 1(B). ISDN exhibited peaks due to C-O, O=NO2, C-
H,–CH2, and N=O stretching as shown in fig. 1. It was observed that 
there were no or very minor changes in main drug peaks in the IR 
spectra of the mixture and pure drug. The FT-IR study revealed no 
physical or chemical interaction of drugs with excipient [19]. 
 
 
Fig. 1(A): FT-IRof ISDN (Indian pharmacopeia) 
 
 
Fig. 1(B): Overlay spectra of ISDNwith all excipients, (I1 = ISDN, I2 = ISDN+MCCPH102, I3 = ISDN+HPMC K100M, I4 = ISDN+polyoxtm 
WSR303, I4 = ISDN+HPMC K15M, I7 = ISDN+Magnesium Stearate) 
 
Table 3: Preliminary screening of polymer 
Batch Hardness (Kg/cm2) Friability (%)  Q1  Q2 Q4  Q6  
T1 3.30±0.08 0.40±0.02 51.09±2.35 90.80±1.57 98.80±.57 99.90±1.89 
T2 3.22±0.06 0.42±0.05 46.03±2.85 85.60±2.47 97.20±1.51 98.60±2.15 
T3 3.18±0.03 0.48±0.03 43.09±2.35 80.80±1.57 96.08±1.57 98.09±1.89 
T4 3.26±0.02 0.46±0.05 38.30±2.85 75.60±2.47 96.07±2.32 98.18±1.65 
T5 3.35±0.04 0.42±0.04 35.20±1.38 74.05±2.48 93.01±1.79 98.58±2.38 
T6 3.28±0.01 0.44±0.07 32.70±2.67 70.08±1.41 90.07±1.81 99.08±1.34 
*All values are mean±SD, (n=6) 
 






WSR303 ® (X2) 
 Q1 (Y1)  Q2 (Y2) 4Q4 (Y3) Q6 (Y4) 
F1 -1 -1  32.70±2.67 70.08±1.41 90.07±1.81 99.83±1.124 
F2 0 -1 31.33±0.57 69.20±0.29 87.9±2.33 98.11±1.32 
F3 1 -1 28.62±0.87 67.23±014 85.3±1.55 97.12±1.544 
F4 -1 0 24.66±0.87 62.34±0.27 82.5±1.89 95.18±1.42 
F5 0 0 21.34±0.59 57.54±0.24 79.3±1.67 94.68±1.21 
F6 1 0 18.66±0.32 53.34±0.17 75.3±2.57 93.43±1.04 
F7 -1 1 15.33±0.25 50.54±0.14 70.4±2.89 92.78±1.67 
F8 0 1 14.63±0.78 48.43±0.27 69.3±2.40 91.38±1.2334 
F9 1 1 13.16±0.85 46.46±0.89 68.9±1.97 90.58±1.31 
Factors and the levels in the design 
Independent variables Low (-1) Medium (0) High (1) 
HPMC K100M (X1) 60 70 80 
POLYOXTM WSR303 (X2) 60 70 80 
*All values are mean±SD, (n=6) 
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Table 5: Evaluation of 32factorial design batches 
Batch Hausner’s ratio Angle of repose(Ө) Weight variation (mg) Thickness (mm) Friability % Drug content % 
F1 1.15±0.05 23.54±0.02 249.40±0.18 4.22±0.03 0.73±0.03 99.40±0.36 
F2 1.14±0.01 22.36±0.09 250.60±0.07 4.57±0.04 0.68±0.15 99.45±1.18 
F3 1.14±0.05 22.38±0.09 251.83±1.07 4.36±0.04 0.73±0.04 99.86±1.52 
F4 1.16±0.05 23.82±0.07 250.50±0.56 4.30±0.05 0.53±0.05 98.13±2.23 
F5 1.18±0.07 25.38±0.06 250.70±0.57 4.28±0.07 0.53±0.03 99.33±1.52 
F6 1.17±0.01 24.80±0.05 250.90±0.78 4.41±0.09 0.44±0.017 99.26±1.32 
F7 1.16±0.02 23.81±0.03 251.43±1.55 4.48±0.02 0.62±0.02 98.60±1.87 
F8 1.16±0.02 23.86±0.31 250.45±0.67 4.42±0.01 0.81±0.45 99.70±0.71 
F9 1.17±0.01 24.85±0.07 250.70±0.56 4.25±0.32 0.59±0.45 99.57±1.47 
*All values are mean±SD, (n=6) 
 
Preliminary screening of polymers for SR layer 
The batches T1 to T6 were prepared to achieve an optimized 
concentration of polymer and the most efficacious one among 
incorporated to prepare SR layer of ISDN 40 mg, as shown by table 1. 
Preliminary trial batches results were shown in table 3. Batch T1 
containing HPMC K4M and Polyoxtm WSR 301 showed 51.09±2.35 % 
drug release at 1 h. Batch T2 and batch T3 were shown 46.03±2.85 % 
and 43.09±2.35 % drug release in 1 h, respectively. While batch T4 
and T5 give, 75.60±2.48% and 74.05±2.48% release in 2 h. Batch T6 
contains HPMC K100M and Polyoxtm WSR 303 that shows 32.70±2.67 
% and 70.08±1.41% drug release at 1 h and 2 h, respectively. Hence, 
further trials were carried out by using a combination of HPMC K100M 
and polyoxtmWSR 303 to understand their effect and optimize the 
concentration of both for the desired release profile [20]. 
32 full factorial design model evaluation 
A statistical model incorporating interactive and polynomial terms 
used to evaluate the responses:  
Y=b0+b1X1+b2X2+b11X12+b22X22+b12X1X2 
Where Y is the dependent variable, bo is the arithmetic mean 
response of the 9 runs and any bi is the estimated coefficients for the 
related factor Xi. The main effects (X1 and X2) represent the average 
result of changing one factor at a time from its low to high value. The 
polynomial terms (X12 and X22) are included to investigate 
nonlinearity. The interaction term “X1X2” shows how the response 
changes when the two factors change simultaneously. Evaluation 
data for SR layer of ISDN 40 mg were presented in table 4 and table 
5. The fitted equations relating the responses that are, Q1 (Y1), % Q2 
(Y2), Q4 (Y3) and % Q6 (Y4) were to the transformed factor are shown 
in table 7. The polynomial equation used to conclude after 
considering the magnitude of coefficient and mathematical sign it 
carries (i.e. positive or negative). The results of ANOVA suggested 
that calculated F values for Q1, Q2, Q4, and Q6 were 084.583, 038.188, 
057.719, and 118.396, respectively, shown in table 6. Tabulated F 
value was found to be 9.013 at α = 0.05. Calculated F values are 
greater than tabulated for all dependent variables. Therefore, the 
factors selected have shown significant effects. From the results of 
multiple regression analysis, it was found that all factors had a 
statistically significant influence on all dependent variables as 
p<0.05 [21, 22]. 
 
Table 6: Results of the ANOVA for dependent variables 
Source of variation DF SS MS F value P value 
Q1* 
Regression 5 437.224 087.445 084.583 0.002 
 Residual 3 003.102 001.034 
Total 8 440.325 055.041 
Q2# 
Regression 5 666.154 133.231 038.188 0.006 
Residual 3 010.467 003.489 
Total 8 676.621 084.578 
Q4@ 
Regression 5 528.985 105.797 057.719 0.004 
Residual 3 005.499 001.833 
Total 8 534.484 066.810 
Q6$ 
Regression 5 76.869 15.374 118.396 0.001 
Residual 3 0.390 0.130 
Total 8 77.259 9.657 
*Q1= % cumulative drug releases at 1 h, #Q2= % cumulative drug releases at 2 h, @Q4= % cumulative drug releases at 4 h, $Q6= % cumulative drug 
releases at 6 h 
 
Table 7: Summary of regression output of factors for measured responses 
Responses Model Coefficient of regression parameters 
b0 b1 b2 b11 b22 b12 R2 
Q1 Full 21.717 2.042 8.255 0.245 1.075 0.478 0.993 
Reduced 21.717 2.042 8.255 - - - 
Q2 Full 57.779 2.655 10.180 0.0583 0.917 0.308 0.959 
Reduced 57.779 2.655 10.180 - - - 
Q4 Full 79.143 2.248 9.090 0.105 0.400 0.797 0.990 
Reduced 79.143 2.248 9.090 - - - 
Q6 Full 94.366 1.110 3.387 0.0967 0.537 0.127 0.995 
Reduced 94.366 1.110 3.387 - - - 
*Q1= % cumulative drug releases at 1 h, #Q2= % cumulative drug releases at 2 h, @Q4= % cumulative drug releases at 4 h, $Q6= % cumulative drug 
releases at 6 h 
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Full and reduced model for Q1 
Q1 = 21.717-(2.042 * X1)-(8.255 * X2)-(0.245 * X12)+(1.075 * 
X22)+(0.478 * X1 X2) 
In this analysis, Q1 ranges were observed between 13.16±0.85% to 
32.7±2.67 %. Based on the analysis of variance (ANOVA) the result 
showed that the developed linear model was highly significant, as 
was evident from a very low probability value 0.002. The value of R2 
was found to be 0.993. The plot of the observed value of Q1 versus 
the predicted value of Q1 (fig. 3B) shows a straight line. Therefore, it 
concluded that the equation has good predictive ability. From the 3D 
plot (fig. 3A) and regression coefficient values of factors, it was 
concluded that when the amount of polymer was increased, drug 
releases was decrease. The polyether chains of polyoxtmWSR303 can 
form strong hydrogen bonds with water; polyoxtmWSR303 upon 
exposure to water or gastric juices, they hydrate and swell rapidly to 
form hydrogels. Therefore, polyoxtm WSR 303 was given a more 
significant effect on drug releases. Interaction and nonlinearity was 
not observed. For Q1, the significance levels of the coefficients b11, b22, 
and b12 were found to be P= 0.756, 0.232, and 0.417, respectively, so 
they were omitted from the full model to generate a reduced model. 
The coefficients b1, and b2 were found to be significant at P<0.05; 
hence, it was retained in the reduced model. The reduced model for 
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Full and reduced model for Q4 
Q4 = 79.143-(2.248 * X1)-(9.090 * X2)-(0.105 * X12)-(0.400 * 
X22)+(0.797 * X1 X2) 
In this analysis, the Q4 ranges were observed between 68.90±1.97% to 
90.70±1.81%. The value of R2 was found to be 0.985. ANOVA analysis 
indicates that the developed linear model was significant, and it shows 
a very low probability value of 0.004. The plot of the observed value of 
Q4 versus the predicted value of Q4 (fig. 4B) shows a straight line. From 
the 3D plot (fig. 4A) and the regression coefficient values of factors, it 
was concluded that when Polyoxtm WSR303 amount was increased Q4 
more decrease compared to the HPMC K100M. It was found that 
higher polymeric content in the matrix decreased the release rate of 
the drug. Interaction and nonlinearity was not observed. For Q4, the 
significance levels of the coefficients b11, b22, and b12 were found to be 
P= 0.920, 0.704, and 0.324, respectively, so they were omitted from 
the full model to generate a reduced model [22]. The coefficients b1 
,and b2 were found to be significant at P<0.05; hence, it was retained in 
the reduced model. The reduced model for Q4 Q4 = 79.143-(2.248 * X1)-






Fig. 5: (A) 3D plot showing the effect of HPMC K100M and Polyoxtm WSR303 on Q6 (B) Predicted Vs actual value of Q6 
 
Full and reduced model for Q6 
Q6 = 94.366-(1.110 * X1)-(3.387 * X2)+(0.0967 * X12)+(0.537 * 
X22)+(0.127 * X1 X2) 
In this analysis, the Q6 ranges were observed between 90.58±1.34% to 
99.83±1.12 %. Based on the analysis of variance (ANOVA) the result 
showed that the developed linear model was highly significant, as was 
evident from a very low probability value 0.001. The value of R2 was 
found to be 0.995. The plot of the observed value of Q6 versus the 
predicted value of Q6 (fig. 5B) shows a straight line. Therefore, it 
concluded that the equation has good predictive ability. Interaction 
and nonlinearity was not observed. From the 3D plot (fig. 5A) and 
regression coefficient values of factors, it was concluded that when the 
amount of polymer was increased, drug releases was decreased. The 
results also indicated that Polyoxtm WSR 303 was given a more 
significant effect on drug releases. For Q6, the significance levels of the 
coefficients b11, b22, and b12 were found to be P= 0.730, 0.126 and 0.530 
respectively, so they were omitted from the full model to generate a 
reduced model. The coefficients b1, and b2 were found to be significant 
at P<0.05; hence, it was retained in the reduced model 
Q6 = 94.366-(1.110 * X1)-(3.387 * X2) 
Search for the selection of optimized formulation 
The optimization of the SR layer of ISDN 40 mg by numerical 
optimization. According to the U. S. P. 2007 the following constraints 
were used for the selection of an optimized batch: Q1=15% to 30%, 
Q2=50% to 70%, Q4=65% to 85% and Q6>75%. Further, the 
optimized SR layer was demarcated in the design space (overlay 
plot) shown in fig. 6. To validate the evolved mathematical models, a 
check-point was selected from its desirability value 1. Check-point 
batch CP1 was prepared and evaluated. The observed and predicted 
values for batch CP1 as shown in table 8. A good correlation was 
found between observed and predicted values. Hence, it was 
concluding that the evolved models might be used for the theoretical 
prediction of responses within the factor space. Optimized SR layer 
gives a 93.40±1.29 % drug release within 6 h. It was kept for 
stability study and in vitro release profile at initial and after 6 mo 
was compared using similarity factor, f2, value that was found to be 
93.078% for SR layer of ISDN. There is no significant difference in 
the similarity factor. 
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Table 8: Formulation and evaluation of check point batches 
Formulation of check point batches 
Batch Code Variable Level 
Coded Value Actual Value 
X1 X2 X1(mg) X2(mg) 
CP1 0 1.11 70.00 77.94 
Evaluation of check point batches and comparison with predicted value 
Parameter Actual value Predicted value 
% Cumulative drug releases at 1 h (Q1) 14.87±0.36 15.708 
% Cumulative drug release at 2 h (Q2) 52.40±1.24 50.259 
% Cumulative drug release at 4 h (Q4 79.40±0.68 71.531 




Fig. 7: In vitro drug release study of bilayer antihypertensive tablet 
 
Evaluation of bilayer tablets 
Finally, the optimized IR layer HHC 25 mg and SR layer ISDN 40 mg 
were prepared separately and two layers compressed together. In 
vitro Release of the bilayer tablet was shown in fig. 7. HHC gives 
100% drug release in 30 min. While ISDN gives 91.67±0.68% in a 
simulated intestinal fluid in 6 h.  
CONCLUSION 
The present investigation was to formulate, evaluate, and optimize 
SR layer containing ISDN 40 mg in a bilayer tablet. There was no 
Drug-excipient interaction in the FT-IR study. From the results of 
preliminary studies, HPMC K100M (X1) and the amount of Polyoxtm 
WSR303 (X2) was chosen as independent variables in 32 full factorial 
design. While Q1 (Y1), Q2 (Y2), Q4 (Y3) and Q6 (Y4), were taken as 
dependent variables. The effect of independent variables on 
dependent variables was studied by analyzing the response surface 
plot and polynomial equation. Optimization of the SR layer of ISDN 
was performed by the overlay plot. A checkpoint batch was designed 
according to the results of the desirability value and evaluated for all 
the parameters. The results of the comparison of predicted response 
and obtained responses were found in good agreement. The 
formulation was found to be stable during accelerated stability 
study. SR of ISDN was helped to prevent tolerance to the prolonged 
use of nitrate. Finally, optimize layers of HHC and optimize layer of 
ISDN were prepared separately, and the two layers compressed 
together. This fixed-dose two times a day therapy has functioned as 
a nitric oxide enhancer and an antioxidant that helps to prevent 
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